Search Results
From bb2121 to bb21217: does bb007 improve efficacy in MM?
Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
Dr. Raje Discusses the Tolerability of bb2121 in Myeloma
Dr. Holstein Discusses Mechanism of bb21217 in Myeloma
How to decide between bispecific antibodies or CAR T-cell therapies
CARTITUDE-1 trial: Is JNJ-4528 safe and efficacious for patients with RRMM?
ide-cel; bb2121, a BCMA-targeted CAR T-cell therapy, in patients with RRMM: Initial KarMMa results
Dr. Berdeja Discusses Next Steps With bb2121 in Multiple Myeloma
Dr. Berdeja Discusses Response to CAR T-Cell Therapy bb2121
Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Pts w/RR Multiple Myeloma
Exciting results from CARTITUDE-1: anti-BCMA CAR-T for MM
KarMMa: Idecabtagene vicleucel for R/R MM
